Real-World Analysis of AMPYRA Multiple Sclerosis Drug Presented by Acorda and HealthCore
Acorda Therapeutics will present results of a study analyzing AMPYRA (dalfampridine) Extended Release Tablets in multiple sclerosis patients at…
Articles by Maureen Newman
Working Memory and Cognitive Reserve Linked in MS Kessler Foundation Study
Any intervention that could help multiple sclerosis patients preserve long-term memory would likely be well-received. As suggested by a recent…
Comorbidities More Prevalent With Multiple Sclerosis Diagnosis
While multiple sclerosis is most typically associated with progressively declining physical ability, multiple sclerosis patients are often times affected…
Novel MS Therapy from GeNeuro Performed Well in Phase 2a Clinical Trial
A novel therapeutic from GeNeuro to treat multiple sclerosis showed promising results in a one-year, open-label extension phase 2a…
Multiple Sclerosis Cases Continue To Rise in Countries With Traditionally Small MS Populations
Recent research continues to suggest that MS is on the rise is countries that in the past posted small…
Low Dose Naltrexone May Improve Multiple Sclerosis Patient Quality of Life
Low dose naltrexone (LDN) may be on its way to becoming a new therapeutic agent for multiple sclerosis. Evidence…
Serum Proteins May Reveal Impending Multiple Sclerosis Symptom Onset
According to new research published in European Journal of Neurology, susceptibility to multiple sclerosis may be…
Multiple Sclerosis Symptoms Aggravated By Genetic Alterations in Patients
While the majority of scientists dedicated to multiple sclerosis research focus on genetic regulators of conditions such as autoimmunity,…
Angiogenesis, VEGF Are Interesting Targets in Treating Multiple Sclerosis
Findings of a number of scientific research articles, reviewed in a recent article from researchers at University…
Low Vitamin D is Linked to Severe Acute Optic Neuritis in Multiple Sclerosis
For the approximately 15-20% of multiple sclerosis patients with acute optic neuritis (AON), lack of vitamin D may be…
Alkermes’ ALKS 8700 to Treat MS is Preparing for a Phase 1 Clinical Trial
Alkermes plc is looking to add one more treatment to the repertoire for multiple sclerosis drugs by initiating a…
Tysabri Protects Against Relapse in Multiple Sclerosis, According To Study
According to a study published in JAMA Neurology, multiple sclerosis patients are greatly benefited by Biogen Idec’s…
Antihistamine Repurposed for Remyelination in Phase 2 Trial from UCSF
The University of California, San Francisco (UCSF) initiated a clinical trial to evaluate the antihistamine clemastine fumarate, manufactured by…
UB Team Finds a Way to Make Stem Cells into Myelinating Cells
Stem therapy to treat multiple sclerosis may benefit greatly from a new study published in Proceedings…
Fatigue in Multiple Sclerosis Linked to Regional Brain Damage
Fatigue, a common symptom of multiple sclerosis, could be a result of regional damage in the brain. A study published…
Long-Term Cognitive Impairment from Multiple Sclerosis Reaffirmed by Kessler Foundation
Researchers at the Kessler Foundation bolstered the knowledge of cognitive decline in multiple sclerosis patients with an article published…
Unique Stem Cell Therapy from StemGenex Studied in Multiple Sclerosis Patients
Multiple sclerosis patients may soon benefit from StemGenex’s leading resource of adult adipose stem cells. StemGenex is now recruiting patients…
Remyelination Strategies for Multiple Sclerosis Presented at Biogen Idec-Sponsored NYAS Conference
On June 26th, a conference devoted to the topic of “Demyelination and Remyelination: From Mechanism to Therapy” will be…
Motor and Sensory Rehabilitation Training Benefits Multiple Sclerosis Patients’ Balance
A study involving a clinical trial treating multiple sclerosis patients with sensory training was published in…
ImStem Uses Embryonic Stem Cells to Treat Animal Model of Multiple Sclerosis
ImStem Biotechnology, Inc. is one step closer to harnessing the power of human embryonic stem cells (hESCs) to treat…
Chronic Cerebrospinal Venous Insufficiency Is Not a Cause of Multiple Sclerosis
Charles Moore, Science and Research Editor of Multiple Sclerosis News Today,…
Biogen Idec Investigates Tysabri in Secondary-Progressive Multiple Sclerosis Patients
Biogen Idec is currently sponsoring a clinical trial evaluating its therapy Tysabri (natalizumab) in patients with secondary-progressive multiple sclerosis. Although…
Interferon Beta-1a Protects Relapse-Remitting MS Patients from Brain Volume Reduction
Research from the State University of New York at Buffalo suggests a protective link between interferon beta-1a treatment and…
Acorda Therapeutics’ Online Multiple Sclerosis Resources To Be Demonstrated in Dallas
At the 2014 Cooperative Meeting of the Consortium of Multiple Sclerosis Centers and the Americas Committee for Treatment and…
Orphan Drug Designation Granted to Treatment for Rare Multiple Sclerosis Drug Complication
The Food and Drug Administration granted Orphan Drug Designation to Inhibikase Therapeutics’, Inc. lead product, IkT-001Pro (imatinib), to treat progressive…
Multiple Sclerosis Disability Linked to Lipid Levels in Australian Study
Patients with multiple sclerosis may benefit from improving blood fats, otherwise known as serum lipids, according to a new…
Brain Receptor More Common to Women May Explain Sex Disparity in Multiple Sclerosis
For years, clinicians and patients could only notice and accept the fact that four times more women than men…
Sun Pharma-Sponsored Phase 3 Trial to Treat Spasticity Due to Multiple Sclerosis in Recruiting Patients
One of the most common and troublesome symptoms of multiple sclerosis is spasticity. Patients with spasticity experience involuntary muscle…
Targeting B-cell Activity May Reduce MS Brain Lesions, According To GlaxoSmithKline-Backed Study
New research work from GlaxoSmithKline presented by Daren Ausin, PhD, at the American Academy of Neurology’s 66th Annual Meeting has…